Is bromelain safe in patients with Chronic Kidney Disease (CKD)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 24, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Safety of Bromelain in Chronic Kidney Disease

Bromelain should be used with caution in patients with chronic kidney disease (CKD) due to limited safety data and potential risks associated with dietary supplements in this vulnerable population.

General Considerations for Supplement Use in CKD

  • Patients with CKD are more susceptible to medication-related adverse effects due to altered pharmacokinetics and reduced drug clearance 1
  • The KDOQI guidelines recommend reviewing and limiting the use of over-the-counter medicines and dietary or herbal supplements that may be harmful for people with CKD 2, 3
  • Polypharmacy (use of 5 or more medications) is common in CKD patients (38-80%), increasing the risk of drug interactions, adverse reactions, and mortality 1

Medication Management in CKD

  • Healthcare providers should establish collaborative relationships with pharmacists to ensure proper drug stewardship in CKD patients 1
  • Regular medication review should be performed to assess for potential drug interactions, as polypharmacy is common in this population 3
  • When prescribing any medication or supplement to CKD patients, always consider the benefits versus potential harms 1, 3

Specific Considerations for Bromelain

  • Bromelain is a mixture of proteolytic enzymes derived from pineapple stems that is commonly used as an anti-inflammatory supplement
  • There is insufficient research specifically evaluating the safety of bromelain in CKD patients
  • Bromelain may have antiplatelet effects and could potentially increase bleeding risk when combined with other anticoagulant or antiplatelet medications 4
  • Multiple pharmacodynamic interactions related to hemorrhage are frequently associated with negative outcomes in older adults with CKD 4
  • 8.5% of CKD patients in one study received combinations of three drugs with antithrombotic or antiplatelet effects, with 64.7% developing hemorrhagic events 4

Monitoring Recommendations

  • Monitor eGFR, electrolytes, and therapeutic medication levels when introducing any new medication or supplement in CKD patients 1, 3
  • Consider potential interactions with other medications the patient may be taking, as 91% of CKD patients have potential drug-drug interactions 5
  • If bromelain is used, start with lower doses and monitor closely for adverse effects, particularly bleeding

Alternative Approaches

  • Non-pharmacologic interventions like exercise therapy (150 minutes per week of moderate-intensity activity) may help manage some conditions for which bromelain is commonly used 1, 6
  • For pain management, carefully weighed alternatives should be considered, as even common analgesics like NSAIDs pose significant risks in CKD 7, 8

Conclusion

  • Given the lack of specific safety data for bromelain in CKD and the general caution advised for supplements in this population, bromelain should be used with caution in CKD patients
  • Any use should involve careful monitoring, consideration of potential drug interactions, and discussion of risks versus benefits with the patient

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Use of Oral Hypoglycemic Agents in Chronic Kidney Disease

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Safety of Sildenafil in Chronic Kidney Disease

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Exercise and chronic kidney disease: current recommendations.

Sports medicine (Auckland, N.Z.), 2005

Research

NSAIDs in CKD: Are They Safe?

American journal of kidney diseases : the official journal of the National Kidney Foundation, 2020

Research

Medication safety in chronic kidney disease.

Current opinion in nephrology and hypertension, 2023

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.